What is the role of disease-modifying therapies (DMT) in the treatment of pediatric multiple sclerosis (MS)?

Updated: Jan 30, 2019
  • Author: Alice K Rutatangwa, DO, MSc; Chief Editor: Amy Kao, MD  more...
  • Print

Ten disease-modifying therapies (DMT) have been approved for treatment of relapsing-remitting multiple sclerosis (MS) in the adult population, including 6 first-line therapies (glatiramer acetate [GA], intramuscular [IM] and subcutaneous [SC] interferon [IFN] beta-1a, and SC interferon-beta-1b, fingolimod [also approved in children], teriflunomide, and dimethyl fumarate) and two second-line therapies (mitoxantrone, alemtuzumab, natalizumab, and ocrelizumab). In addition, therapies such as rituximab and cyclophosphamide have been evaluated in phase II trials in adults with breakthrough disease, as have add-on therapies such as monthly steroids and intravenous immunoglobulin (IVIG).

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!